What's new?

Montpellier, September 18, 2020 – Sensorion (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announce...

September 17, 2020 – Paris, France   Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a €3.5M seed financing from Sofinnova Partners to support the development of its intravascul...

HBM Healthcare Investments joins lead investor Sofinnova Partners and New Enterprise Associates in consortium   September 16, 2020 01:30 AM Eastern Daylight Time BASEL, Switzerland--(BUSINESS WIRE)--Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of antigen-specific polymers for the treatme...

Recognition of Biotalys’ unique protein-based biocontrol solutions for food protection   GHENT, Belgium and RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today announced that it won the “Crop Protection Solution of the Year” and the ...

Redx will lead discovery and preclinical development activities on two cancer targets

STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at €2.80 per share in an off-market transaction. Following the closing of the control transaction a mandatory simplified c...

Appointment of Non-Executive Director and changes to Board committees   Alderley Park, 5 August 2020 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce, following the successful completion of the loan note fundraising and receipt of funds, the a...

Redx signs out licensing agreement with AstraZeneca   AstraZeneca granted exclusive global licence for the development and commercialisation of RXC006, a porcupine inhibitor, for fibrotic diseases Redx will receive up to $17 million in early payments between deal signature and the successful commencement of first c...

Seasoned Medical Executive to Commercialize CorVent's RESPOND-19™ Ventilator

Serial entrepreneur brings exceptional experience from a range of leadership roles   Italy, Milan, 30 July 2020: Genespire, a gene therapy company developing transformative therapies for genetic diseases, today announces the appointment of Jörn Aldag as Chairman of the Board.